Colpeptin1 Peptide Induces Bacterial Protein Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing problem of antibacterial resistance, particularly in Gram-negative bacteria, such as enterohemorrhagic E. coli, which produces high levels of toxins leading to severe infections, necessitates the development of novel antimicrobial peptides that can induce misfolding or aggregation of multiple bacterial proteins, making it difficult for bacteria to develop resistance.
Innovation Solution
Identification of non-naturally occurring peptides, like colpeptin1, that contain aggregation-nucleating sequences redundant in the E. coli proteome, which induce rapid and efficient aggregation of multiple bacterial proteins, leading to proteostatic collapse and bacterial death, while showing minimal toxicity to mammalian cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat bacterial infections, then bacterial growth is inhibited, but bacterial resistance develops rapidly
Solution Approach 1:
The patent converts the naturally occurring harmful aggregation of bacterial proteins into a beneficial therapeutic effect. Aggregating peptides are designed to induce controlled protein aggregation in bacteria, leading to proteostatic collapse and cell death. This transforms the normally detrimental aggregation process into a selective antibacterial mechanism that spares mammalian cells with robust proteostasis networks.
Solution Approach 2:
The invention changes the fundamental mechanism of action from traditional antibiotic targets (cell wall synthesis, protein synthesis, DNA replication) to proteostasis disruption. By altering the parameter of protein aggregation susceptibility, the peptides exploit differences between bacterial and mammalian proteostasis networks to achieve selective toxicity.
2Speed
If protein aggregation is induced in bacteria to kill them, then bacterial death occurs rapidly, but specificity against mammalian cells must be maintained
Solution Approach 1:
The patent applies local quality by targeting specific bacterial proteins with aggregation-prone regions that are unique to bacterial proteomes. The aggregating peptides are designed to bind specifically to bacterial protein sequences, inducing aggregation only in bacterial cells while leaving mammalian cells unaffected due to their different protein sequences and robust proteostasis networks.
Solution Approach 2:
The aggregating peptides exploit the inherent aggregation susceptibility of bacterial proteins as a self-service mechanism. Once inside the bacterial cell, the peptides trigger a cascade of protein aggregation that the bacterial proteostasis network cannot prevent, leading to autonomous cell death without requiring additional toxic mechanisms.
3Quantity of substance
If traditional antibiotics are used, then treatment costs increase for drug-resistant infections, but novel peptide therapies require extensive development
Solution Approach 1:
The aggregating peptides exhibit broad-spectrum activity against multiple Gram-negative bacterial pathogens, including E. coli, P. aeruginosa, and K. pneumoniae. A single peptide design strategy can target multiple bacterial species by exploiting the universal vulnerability of bacterial proteostasis networks to protein aggregation, reducing the need for pathogen-specific drug development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Colpeptin1 and similar peptides effectively reduce bacterial loads in vivo without adverse effects on the host, demonstrating a novel paradigm for antibiotic development by exploiting sequence-specific protein aggregation to achieve fast and lethal bacterial cell death, with no resistance development observed even after prolonged exposure.
Implementation Method 1
the peptides are internalized by E. coli as 98% of the cells were positive within 15 min. Colpeptin1 uptake readily resulted in the formation of large polar inclusion bodies and bacterial cell death
Data Source
AI summary
The present invention relates to non-naturally occurring anti-bacterial peptides. More specifically the peptides can be used to treat multi-drug resistant bacterial infections. In addition, the present invention provides methods for producing anti-bacterial peptides.